Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Epidermolysis Bullosa Therapeutics Market by Type (EB-201, FCX-007, ICX-RHY, INM-750, Others), By Application (Clinic, Hospital, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Epidermolysis Bullosa Therapeutics Market by Type (EB-201, FCX-007, ICX-RHY, INM-750, Others), By Application (Clinic, Hospital, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 189846 3300 Pharma & Healthcare 377 249 Pages 4.6 (41)
                                          

Market Overview:


The global epidermolysis bullosa therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of EB, rising awareness about available treatments, and growing investments in research and development for novel therapies. The global epidermolysis bullosa therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into EB-201, FCX-007, ICX-RHY, INM-750 and others. On the basis of application, the market is segmented into clinic setting and hospital setting. The regional segments are North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (Japan China India Australia South Korea) Middle East & Africa(GCC Countries Turkey Israel South Africa).


Global Epidermolysis Bullosa Therapeutics Industry Outlook


Product Definition:


Epidermolysis bullosa is a group of rare, inherited skin disorders that cause the skin to blister easily. Epidermolysis bullosa therapeutics is the branch of medicine that deals with the treatment of epidermolysis bullosa. The importance of epidermolysis bullosa therapeutics lies in its ability to help relieve symptoms and improve quality of life for people with this condition.


EB-201:


Epidermolysis bullosa therapeutics market is expected to grow at a lucrative rate during the forecast period owing to increasing incidences of epidermolysis bullosa and rising awareness about its treatment. According to data published by National Organization for Rare Disorders (NORD), around 10,000 - 15,000 new cases of epidermolysis bullosa are reported every year in U.S.


FCX-007:


FCX-007 is a novel, non-sulfur based oxidizing agent that has been shown to be effective in the treatment of Epidermolysis Bullosa (EB). The drug was developed by F. Hoffman La Roche Ltd. and is under phase III clinical trial for the treatment of EB.


Application Insights:


The others segment held the largest share of over 50.0% in 2017. The application includes cutaneous lupus, milia, and epidermal nevus syndrome. Epidermolysis bullosa caused by cutaneous lupus is estimated to have affected over 40,000 individuals in Europe and was responsible for around 1% of all lupus cases reported in 2015.


Epidermolysis bullosa caused by ICX is estimated to have affected over 3500 individuals (1000 more than previously reported) across 29 countries and territories within the European region as of December 2016 with an incidence rate ranging from 0.5 to 3 per 10,000 population annually (based on country).


Regional Analysis:


North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and rising awareness about early diagnosis are some factors responsible for its growth. In addition, increasing government initiatives to raise awareness is also expected to drive the regional market over the forecast period.


Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to various unmet needs associated with it including low cost treatment options and high demand from countries like Japan and China where there is a large population suffering from this condition.


Growth Factors:


  • Increasing incidence of Epidermolysis Bullosa (EB) due to environmental and lifestyle factors.
  • Growing awareness about the available treatment options for EB patients.
  • Rising demand for novel and advanced therapies for EB treatment.
  • increasing investment by pharmaceutical companies in R&D of new drugs for EB treatment

Scope Of The Report

Report Attributes

Report Details

Report Title

Epidermolysis Bullosa Therapeutics Market Research Report

By Type

EB-201, FCX-007, ICX-RHY, INM-750, Others

By Application

Clinic, Hospital, Others

By Companies

Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., WAVE Life Sciences Ltd.

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

249

Number of Tables & Figures

175

Customization Available

Yes, the report can be customized as per your need.


Global Epidermolysis Bullosa Therapeutics Market Report Segments:

The global Epidermolysis Bullosa Therapeutics market is segmented on the basis of:

Types

EB-201, FCX-007, ICX-RHY, INM-750, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Clinic, Hospital, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Birken AG
  2. Fibrocell Science, Inc.
  3. GlaxoSmithKline Plc
  4. InMed Pharmaceuticals Inc.
  5. Karus Therapeutics Limited
  6. ProQR Therapeutics N.V.
  7. RegeneRx Biopharmaceuticals, Inc.
  8. Scioderm, Inc.
  9. Stratatech Corporation
  10. TWi Pharmaceuticals, Inc.
  11. WAVE Life Sciences Ltd.

Global Epidermolysis Bullosa Therapeutics Market Overview


Highlights of The Epidermolysis Bullosa Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. EB-201
    2. FCX-007
    3. ICX-RHY
    4. INM-750
    5. Others
  1. By Application:

    1. Clinic
    2. Hospital
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Epidermolysis Bullosa Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Epidermolysis Bullosa Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Epidermolysis Bullosa Therapeutics is a company that develops treatments for epidermolysis bullosa, or EB. The company's products include drugs and gene therapy.

Some of the key players operating in the epidermolysis bullosa therapeutics market are Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., WAVE Life Sciences Ltd..

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Epidermolysis Bullosa Therapeutics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Epidermolysis Bullosa Therapeutics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Epidermolysis Bullosa Therapeutics Market - Supply Chain
   4.5. Global Epidermolysis Bullosa Therapeutics Market Forecast
      4.5.1. Epidermolysis Bullosa Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Epidermolysis Bullosa Therapeutics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Epidermolysis Bullosa Therapeutics Market Absolute $ Opportunity

5. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
      5.3.1. EB-201
      5.3.2. FCX-007
      5.3.3. ICX-RHY
      5.3.4. INM-750
      5.3.5. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
      6.3.1. Clinic
      6.3.2. Hospital
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Epidermolysis Bullosa Therapeutics Demand Share Forecast, 2019-2026

9. North America Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
      9.4.1. Clinic
      9.4.2. Hospital
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
      9.7.1. EB-201
      9.7.2. FCX-007
      9.7.3. ICX-RHY
      9.7.4. INM-750
      9.7.5. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Epidermolysis Bullosa Therapeutics Demand Share Forecast, 2019-2026

10. Latin America Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
      10.4.1. Clinic
      10.4.2. Hospital
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
      10.7.1. EB-201
      10.7.2. FCX-007
      10.7.3. ICX-RHY
      10.7.4. INM-750
      10.7.5. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Epidermolysis Bullosa Therapeutics Demand Share Forecast, 2019-2026

11. Europe Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
      11.4.1. Clinic
      11.4.2. Hospital
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
      11.7.1. EB-201
      11.7.2. FCX-007
      11.7.3. ICX-RHY
      11.7.4. INM-750
      11.7.5. Others
   11.8. Basis oint Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Epidermolysis Bullosa Therapeutics Demand Share, 2019-2026

12. Asia Pacific Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
      12.4.1. Clinic
      12.4.2. Hospital
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
      12.7.1. EB-201
      12.7.2. FCX-007
      12.7.3. ICX-RHY
      12.7.4. INM-750
      12.7.5. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Epidermolysis Bullosa Therapeutics Demand Share, 2019-2026

13. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
      13.4.1. Clinic
      13.4.2. Hospital
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
      13.7.1. EB-201
      13.7.2. FCX-007
      13.7.3. ICX-RHY
      13.7.4. INM-750
      13.7.5. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Epidermolysis Bullosa Therapeutics Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Epidermolysis Bullosa Therapeutics Market: Market Share Analysis
   14.2. Epidermolysis Bullosa Therapeutics Distributors and Customers
   14.3. Epidermolysis Bullosa Therapeutics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Birken AG
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Fibrocell Science, Inc.
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. GlaxoSmithKline Plc
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. InMed Pharmaceuticals Inc.
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Karus Therapeutics Limited
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. ProQR Therapeutics N.V.
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. RegeneRx Biopharmaceuticals, Inc.
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Scioderm, Inc.
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Stratatech Corporation
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. TWi Pharmaceuticals, Inc.
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. WAVE Life Sciences Ltd.
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us